



Treatment pathways

Summary versions

Published: 11 August 2022

Last updated: 8 March 2024

www.nice.org.uk

We have produced treatment pathways bringing together NICE recommended treatment options from this guideline and relevant technology appraisal guidance on advanced non-small-cell lung cancer (squamous and non-squamous). The treatment pathways cover the recommended treatment options at each decision point.

These are available to view as individual pathways (linked below), or grouped together in a single [interactive PDF of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer](#).

We have also produced [fully accessible summaries of the treatment pathways](#).

Squamous non-small-cell lung cancer

No targetable mutations, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%](#)

No targetable mutations, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher](#)

RET fusion positive, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

RET fusion positive, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

KRAS G12C positive, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

KRAS G12C positive, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

METex14 skipping alteration, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

METex14 skipping alteration, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

BRAF V600 positive, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

BRAF V600 positive, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

Non-squamous non-small-cell lung cancer

No targetable mutations, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%](#)

No targetable mutations, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher](#)

RET fusion positive, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

RET fusion positive, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

KRAS G12C positive, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

KRAS G12C positive, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

METex14 skipping alteration, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

METex14 skipping alteration, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

BRAF V600 positive, PD-L1 less than 50%

[Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%](#)

BRAF V600 positive, PD-L1 50% or higher

[Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

[Fully accessible summary of Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher](#)

ROS-1 positive

[Systemic anti-cancer therapy: treatment options for people with ROS-1 positive non-squamous non-small-cell lung cancer](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with ROS-1 positive non-squamous non-small-cell lung cancer](#)

EGFR-TK positive

[Systemic anti-cancer therapy: treatment options for people with EGFR-TK positive non-squamous non-small-cell lung cancer](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with EGFR-TK positive non-squamous non-small-cell lung cancer](#)

ALK positive

[Systemic anti-cancer therapy: treatment options for people with ALK positive non-squamous non-small-cell lung cancer](#)

[Fully accessible summary of systemic anti-cancer therapy: treatment options for people with ALK positive non-squamous non-small-cell lung cancer](#)